Health & Fitness
Health and Fitness
Health and Fitness
Tue, May 25, 2010
Mon, May 24, 2010 ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming ASCO Annual Meeting
WALTHAM, Mass.--([ BUSINESS WIRE ])--[ ImmunoGen, Inc. ] (Nasdaq: IMGN), a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that there will be several clinical data presentations for compounds utilizing the Companya™s Targeted Antibody Payload (TAP) technology at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago on June 4-8, 2010.
"These presentations at ASCO will include the first clinical data for our IMGN388 compound for solid tumors, and also the first data for a TAP compound used in a combination regimen"
aThese presentations at ASCO will include the first clinical data for our IMGN388 compound for solid tumors, and also the first data for a TAP compound used in a combination regimen,a commented Daniel Junius, President and CEO. aOur clinical pipeline not only continues to grow through progress with additional TAP compounds, but also to mature through an increase in planned and ongoing advanced clinical trials.a
TAP-Related Presentations and Discussions at ASCO
Abstract #1012: A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab for women with HER2-positive, locally advanced or metastatic breast cancer who were previously treated with trastuzumab
- Poster presentation: Saturday, June 5, 8:00 am - 12:00 noon in E450b
- Poster discussion session: Saturday, June 5, 12:00 noon - 1:00 pm in E Hall D1
Abstract #1016: Quantitative assessment of diagnostic markers and correlations with efficacy in two phase II studies of trastuzumab-DM1 (T-DM1) for patients with metastatic breast cancer who had progressed on prior HER2-directed therapy
- Poster presentation: Saturday, June 5, 8:00 am - 12:00 noon in E450b
- Poster discussion session: Saturday, June 5, 12:00 noon - 1:00 pm in E Hall D1
Abstract #3058: A phase I dose-escalation study of IMGN388 in patients with solid tumors
- Poster presentation: Monday, June 7, 8:00 am - 12:00 noon in S Hall A2
Additionally, John Lambert, Ph.D., Executive Vice President and Chief Scientific Officer of ImmunoGen, will be participating on the panel, aNew Targeted Therapies for Resistant Cancersa being held on Monday, June 7, in conjunction with ASCO.
About ImmunoGena™s Targeted Antibody Payload (TAP) Technology
The Companya™s TAP technology uses antibodies to deliver one of ImmunoGena™s proprietary cancer-cell killing agents (e.g., DM1, DM4) specifically to tumors. ImmunoGen developed these agents specifically for targeted delivery to tumor cells. They are many-fold more potent than standard chemotherapeutics and are designed to be attached to antibodies using one of the Companya™s engineered linkers. In addition to T-DM1 and IMGN388, four other compounds that make use of ImmunoGena™s TAP technology are in clinical testing.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cancer-cell killing agents. The Companya™s TAP technology uses antibodies to deliver one of ImmunoGena™s proprietary cancer-cell killing agents specifically to tumors. In addition to the Companya™s product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGena™s collaborations with Genentech (a wholly-owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in PhaseIII testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer Schering Pharma and Amgen. More information about ImmunoGen can be found at [ www.immunogen.com ].
This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including T-DM1 and IMGN388, including risks related to uncertainties around clinical trials conducted and their timings and results. A review of these risks can be found in ImmunoGena™s Annual Report on Form 10-K for the fiscal year ended June 30, 2009 and other reports filed with the Securities and Exchange Commission.
